Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

However, the company's high debt load is a concern. Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst, drugs like Entresto, Kesimpta, Pluvicto, Kisqali and Leqvio continue ...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

Another point of concern for BofA Securities is the potential impact of the upcoming Kisqali patent litigation outcome. Should the decision fall unfavorably for Novartis, it could lead to a ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Novartis, meanwhile, is also looking to muscle in on the adjuvant setting with the NATALEE trial of Kisqali, due to generate results later this year. The CDK 4/6 drug made $1.2 billion in sales ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Bremen (Novartis Pharma GmbH) Oct 18, 2024 Process Expert (m/f/d) – Part-time (50%) Regulär, Part time Innovative Medicines Austria Schaftenau Oct 18, 2024 Medical Scientific Liaison Manager, ...

Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,666.61 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...

At close: November 8 at 3:00 PM EST ...